– USA, MA – Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced the appointment of Dr. Jeffrey Chodakewitz, M.D., to its board of directors.
The Company also announced that Dr. Nicholas Galakatos and Dr. Kiran Reddy have resigned from its board of directors.
About Dr. Chodakewitz
Dr. Chodakewitz has more than 30 years of management experience in the biopharmaceutical industry. Most recently he served as the chief medical officer and EVP, global medicines development & medical affairs at Vertex Pharmaceuticals. Before Vertex, Dr. Chodakewitz spent over 20 years at Merck & Co. serving in several positions, including leadership roles as head of infectious diseases and vaccines global development, senior vice president of global scientific strategy (infectious disease, respiratory & immunology), and senior vice president of late-stage development.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance. Praxis is applying insights from genetic epilepsies to broader neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio, including multiple disclosed programs across CNS disorders including depression, epilepsy, movement disorders, and pain syndromes, with three clinical-stage product candidates.
For more information: https://praxismedicines.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
